View Item 

Show simple item record

Real- world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A follow- up retrospective analysis
dc.contributor.authorCarcao, Manuel
dc.contributor.authorShapiro, Amy
dc.contributor.authorHwang, Nina
dc.contributor.authorPipe, Steven
dc.contributor.authorAhuja, Sanjay
dc.contributor.authorLieuw, Ken
dc.contributor.authorStaber, Janice M.
dc.contributor.authorBelletrutti, Mark
dc.contributor.authorSun, Haowei Linda
dc.contributor.authorDing, Hilda
dc.contributor.authorWang, Michael
dc.contributor.authorPrice, Victoria
dc.contributor.authorSteele, MacGregor
dc.contributor.authorTsao, Elisa
dc.contributor.authorFeng, Jing
dc.contributor.authorAl‐khateeb, Zahra
dc.contributor.authorDumont, Jennifer
dc.contributor.authorJain, Nisha
dc.date.accessioned2021-03-02T21:45:07Z
dc.date.available2022-02-02 16:45:05en
dc.date.available2021-03-02T21:45:07Z
dc.date.issued2021-01
dc.identifier.citationCarcao, Manuel; Shapiro, Amy; Hwang, Nina; Pipe, Steven; Ahuja, Sanjay; Lieuw, Ken; Staber, Janice M.; Belletrutti, Mark; Sun, Haowei Linda; Ding, Hilda; Wang, Michael; Price, Victoria; Steele, MacGregor; Tsao, Elisa; Feng, Jing; Al‐khateeb, Zahra ; Dumont, Jennifer; Jain, Nisha (2021). "Real- world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A follow- up retrospective analysis." Haemophilia (1): 19-25.
dc.identifier.issn1351-8216
dc.identifier.issn1365-2516
dc.identifier.urihttps://hdl.handle.net/2027.42/166393
dc.publisherWiley Periodicals, Inc.
dc.subject.otherhaemophilia A
dc.subject.otherretrospective chart review
dc.subject.otherimmune tolerance induction
dc.subject.otherinhibitor
dc.subject.otherrecombinant factor VIII Fc fusion protein
dc.subject.otherrescue therapy
dc.titleReal- world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A follow- up retrospective analysis
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/166393/1/hae14192_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/166393/2/hae14192.pdf
dc.identifier.doi10.1111/hae.14192
dc.identifier.sourceHaemophilia
dc.identifier.citedreferenceKrishnamoorthy S, Liu T, Drager D, et al. Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice. Cell Immunol. 2016; 301: 30 - 39.
dc.identifier.citedreferenceOldenburg J, Jiménez- Yuste V, Peiró- Jordán R, Aledort LM, Santagostino E. Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF- containing plasma- derived FVIII concentrate. Haemophilia. 2014; 20: 83 - 91.
dc.identifier.citedreferenceHay CRM, DiMichele DM, International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012; 119: 1335 - 1344.
dc.identifier.citedreferenceCarcao M, Shapiro A, Staber JM, et al. Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors- A retrospective analysis. Haemophilia. 2018; 24: 245 - 252.
dc.identifier.citedreferenceMalec LM, Journeycake J, Ragni MV. Extended half- life factor VIII for immune tolerance induction in haemophilia. Haemophilia. 2016; 22: e552 - e554.
dc.identifier.citedreferenceSanofi. ELOCTATE® prescribing information; 2019.
dc.identifier.citedreferenceCarcao M, Escuriola- Ettingshausen C, Santagostino E, et al. Future of Immunotolerance Treatment Group. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia. 2019; 25: 676 - 684.
dc.identifier.citedreferenceSu J, Zhou J, Buckley B, Hou Q, Jain N. Utilizations and costs of bypass therapies for the management of hemophilia A patients with inhibitors. Haemophilia. 2017; 23: 87 - 88.
dc.identifier.citedreferenceEarnshaw SR, Graham CN, McDade CL, Spears JB, Kessler CM. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on- demand with bypass treatment. Haemophilia. 2015; 21: 310 - 319.
dc.identifier.citedreferenceNakar C, Manco- Johnson MJ, Lail A, et al. Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two U.S. centres. Haemophilia. 2015; 21: 365 - 373.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hae14192_am.pdf
Size:
219.6KB
Format:
PDF
View/Open
Name:
hae14192.pdf
Size:
394.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.